Treatment of @entity4536 with a combination of XXXX and low-dose @entity17004 .

@entity1 @entity17004 @entity3667 @entity4536 @entity208
The objective of this study was to compare the efficacy of a combination of @entity208 (AL) and low-dose @entity17004 (MA) with standard-dose MA in @entity4536 caused by @entity3667 . An open, controlled study was performed. Seventy-two @entity1 were randomly selected from volunteers with @entity4536 living in a hyperendemic area. Exclusion criteria included pregnancy, nursing vs. gestation, age less than 5 years, and duration of disease of more than 4 months. Each @entity1 received MA (60 mg/kg/day) or AL (20 mg/kg/day) plus low-dose MA (30 mg/kg/day) for 20 days, and was followed up for 30 days after cessation of treatment. The study was completed as planned in 66 @entity1 . Complete healing occurred in 74.2% of @entity1 in the MA group and in 80.6% of @entity1 in the MA + AL group. No difference was found between the two groups with respect to side-effects. The combination of AL and MA increases the anti-leishmanial effects of antimoniate. In this study, it was confirmed that low-dose MA plus AL is as effective as high-dose MA in the treatment of @entity4536 caused by @entity3667 .
